首页> 外文期刊>Respiration: International Review of Thoracic Diseases >Itraconazole comedication increases systemic levels of inhaled fluticasone in lung transplant recipients.
【24h】

Itraconazole comedication increases systemic levels of inhaled fluticasone in lung transplant recipients.

机译:伊曲康唑喜剧增加了肺移植接受者吸入氟替卡松的全身水平。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: After lung transplantation (LTx), inhaled corticosteroids may be prescribed and at the same time prophylaxis against fungal infections with itraconazole is common. In our center, the addition of inhaled fluticasone propionate to systemic immunosuppression resulted in clinical Cushing's syndrome in 4 lung transplant recipients on itraconazole comedication. OBJECTIVES: The current study was undertaken to compare systemic levels of inhaled fluticasone in patients with and without concomitant itraconazole therapy. METHODS: The single-center, prospective controlled study was performed in the LTx program in Zurich, Switzerland. Twenty stable recipients, 1-7 years after LTx, on a prednisone maintenance dose (5-7.5 mg/day) gave informed consent and were assigned to 2 groups: (A) without itraconazole comedication and (B) currently on itraconazole, being continued during the study period. The patients of both groups started inhalation of 1 mg fluticasone propionate twice daily for 14 days with a powder disc inhaler. Plasma fluticasone levels were measured before the start of the study and on day 14. RESULTS: Fluticasone levels before starting the treatment were below the detection limit in all 17 patients (7 in group A and 10 in group B) adhering to the study protocol. Baseline characteristics (underlying disease, age at LTx, time since LTx, FEV(1)) were comparable between the 2 groups. On study day 14, plasma fluticasone levels had increased to detectable levels in all patients (A: 273 +/- 124 pg/ml, B: 701 +/- 131 pg/ml), i.e. to significantly higher (p = 0.038) concentrations in patients on itraconazole. CONCLUSIONS: Itraconazole comedication substantially increases systemic levels of inhaled fluticasone, most likely by inhibiting the cytochrome P450 3A4 enzyme system and thus the clearance of fluticasone. Accumulation of fluticasone can result in increased systemic effects and therefore comedication has to be taken into consideration when inhaled fluticasone is prescribed.
机译:背景:进行肺移植(LTx)后,可能会开具吸入皮质类固醇的处方,与此同时,预防伊曲康唑真菌感染的方法很普遍。在我们中心,在全身免疫抑制中加入丙酸氟替卡松吸入后,在接受伊曲康唑喜剧治疗的4名肺移植受者中导致了临床库欣综合征。目的:本研究旨在比较接受和不接受伊曲康唑治疗的患者吸入氟替卡松的全身水平。方法:在瑞士苏黎世的LTx程序中进行了单中心,前瞻性对照研究。 LTx 1-7年后,接受泼尼松维持剂量(5-7.5 mg /天)的二十名稳定接受者表示知情同意,并分为两组:(A)无伊曲康唑喜剧治疗;(B)目前接受伊曲康唑喜剧治疗,正在继续在学习期间。两组患者均开始使用粉碟吸入器每天两次吸入1 mg丙酸氟替卡松,持续14天。在研究开始之前和第14天测量血浆氟替卡松的水平。结果:在开始研究治疗前,所有17例患者(坚持A组7例,B组10例)的氟替卡松水平均低于检出限。两组之间的基线特征(潜在疾病,LTx的年龄,LTx发生的时间,FEV(1))相当。在第14天的研究中,所有患者的血浆氟替卡松水平均增加到可检测的水平(A:273 +/- 124 pg / ml,B:701 +/- 131 pg / ml),即明显升高(p = 0.038)在伊曲康唑上的患者。结论:伊曲康唑的喜剧性药物可显着增加吸入性氟替卡松的全身水平,这很可能是通过抑制细胞色素P450 3A4酶系统从而抑制氟替卡松的清除而实现的。氟替卡松的积累可导致全身作用增加,因此,开具吸入性氟替卡松处方时必须考虑喜剧。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号